Is VTRS or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.79% 20.02% 8.02% Belite Bio N/A -11.84% -11.62%

Belite Bio (BLTE) Competitors

$169.44 +0.77 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$169.62 +0.19 (+0.11%)

As of 07:30 PM Eastern

Compare

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Belite Bio stock or one of its competitors? Belite Bio's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Belite Bio compare to Viatris?

Viatris (NASDAQ:VTRS) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Belite Bio has a net margin of 0.00% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Belite Bio	N/A	-11.84%	-11.62%

Viatris presently has a consensus target price of $19.50, suggesting a potential upside of 11.94%. Belite Bio has a consensus target price of $218.73, suggesting a potential upside of 29.09%. Given Belite Bio's higher possible upside, analysts plainly believe Belite Bio is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Viatris had 4 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Viatris and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Viatris' score of 0.76 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Viatris	Positive
Belite Bio	Very Positive

Viatris has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Viatris. Belite Bio is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.36	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Viatris beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has lower revenue, but higher earnings than Jazz Pharmaceuticals. Belite Bio is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.59	-$356.15M	$14.50	16.30
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Jazz Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Belite Bio's net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Belite Bio	N/A	-11.84%	-11.62%

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Jazz Pharmaceuticals and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Jazz Pharmaceuticals' score of 0.76 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Jazz Pharmaceuticals	Positive
Belite Bio	Very Positive

Jazz Pharmaceuticals currently has a consensus price target of $289.37, indicating a potential upside of 22.47%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 29.09%. Given Belite Bio's higher probable upside, analysts clearly believe Belite Bio is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Jazz Pharmaceuticals beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Neurocrine Biosciences has a net margin of 20.91% compared to Belite Bio's net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Belite Bio	N/A	-11.84%	-11.62%

Neurocrine Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market.

Neurocrine Biosciences currently has a consensus price target of $201.09, indicating a potential upside of 44.73%. Belite Bio has a consensus price target of $218.73, indicating a potential upside of 29.09%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Neurocrine Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	4.94	$478.60M	$6.82	20.37
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 7 more articles in the media than Belite Bio. MarketBeat recorded 8 mentions for Neurocrine Biosciences and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Neurocrine Biosciences' score of 1.04 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Neurocrine Biosciences	Positive
Belite Bio	Very Positive

Summary

Neurocrine Biosciences beats Belite Bio on 14 of the 16 factors compared between the two stocks.

How does Belite Bio compare to Corcept Therapeutics?

Belite Bio (NASDAQ:BLTE) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Belite Bio currently has a consensus target price of $218.73, indicating a potential upside of 29.09%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 16.59%. Given Belite Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 22 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for Corcept Therapeutics and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Corcept Therapeutics' score of 0.53 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Very Positive
Corcept Therapeutics	Positive

Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Corcept Therapeutics	$761.41M	16.83	$99.65M	$0.42	282.17

Corcept Therapeutics has a net margin of 6.52% compared to Belite Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Corcept Therapeutics	6.52%	8.26%	6.45%

Summary

Corcept Therapeutics beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Belite Bio compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market.

In the previous week, Elanco Animal Health had 6 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for Elanco Animal Health and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.76 beat Elanco Animal Health's score of 0.46 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Elanco Animal Health	Neutral
Belite Bio	Very Positive

Elanco Animal Health currently has a consensus price target of $29.70, suggesting a potential upside of 33.03%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 29.09%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Elanco Animal Health is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio has lower revenue, but higher earnings than Elanco Animal Health. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.37	-$232M	-$0.41	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Belite Bio has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Belite Bio	N/A	-11.84%	-11.62%

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Belite Bio on 11 of the 15 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLTE vs. The Competition

Export

Metric	Belite Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.06B	$12.62B	$7.32B	$13.29B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-62.07	789.89	274.40	25.76
Price / Sales	N/A	811.45	639.79	86.88
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	8.25	10.69	10.52	6.34
Net Income	-$77.61M	$2.83B	$3.49B	$360.00M
7 Day Performance	-0.53%	-0.69%	-1.08%	-0.11%
1 Month Performance	6.65%	-1.10%	-3.39%	-3.42%
1 Year Performance	142.75%	2.10%	15.08%	5.46%

Belite Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLTE Belite Bio	3.7745 of 5 stars	$169.44 +0.5%	$218.73 +29.1%	+137.4%	$7.06B	N/A	N/A	41	Positive News
VTRS Viatris	3.6961 of 5 stars	$16.42 -1.5%	$18.57 +13.1%	+78.3%	$18.84B	$14.74B	N/A	30,000	News Coverage Analyst Forecast
JAZZ Jazz Pharmaceuticals	4.2372 of 5 stars	$243.61 -0.9%	$286.72 +17.7%	+81.5%	$15.76B	$4.60B	16.74	2,890	Analyst Forecast
NBIX Neurocrine Biosciences	4.834 of 5 stars	$152.48 -3.0%	$201.09 +31.9%	-4.7%	$15.50B	$3.37B	22.36	2,000
CORT Corcept Therapeutics	3.4886 of 5 stars	$110.78 -0.9%	$138.17 +24.7%	+35.5%	$11.97B	$761.41M	263.72	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLTE) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Summary

How does Belite Bio compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Belite Bio (BLTE) Competitors

BLTE vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Belite Bio compare to Viatris?

Is VTRS or BLTE more profitable?

Do analysts prefer VTRS or BLTE?

Does the media prefer VTRS or BLTE?

Which has more risk & volatility, VTRS or BLTE?

Which has stronger earnings and valuation, VTRS or BLTE?

Do insiders and institutionals hold more shares of VTRS or BLTE?

Summary

How does Belite Bio compare to Jazz Pharmaceuticals?

Do insiders and institutionals have more ownership in JAZZ or BLTE?

Which has stronger valuation & earnings, JAZZ or BLTE?

Which has more volatility & risk, JAZZ or BLTE?

Is JAZZ or BLTE more profitable?

Does the media prefer JAZZ or BLTE?

Do analysts prefer JAZZ or BLTE?

Summary

How does Belite Bio compare to Neurocrine Biosciences?

Is NBIX or BLTE more profitable?

Which has more risk and volatility, NBIX or BLTE?

Do analysts rate NBIX or BLTE?

Which has better valuation and earnings, NBIX or BLTE?

Do insiders & institutionals believe in NBIX or BLTE?

Does the media prefer NBIX or BLTE?

Summary

How does Belite Bio compare to Corcept Therapeutics?

Do analysts rate BLTE or CORT?

Do insiders & institutionals hold more shares of BLTE or CORT?

Does the media refer more to BLTE or CORT?

Which has more volatility & risk, BLTE or CORT?

Which has higher earnings & valuation, BLTE or CORT?

Is BLTE or CORT more profitable?

Summary

How does Belite Bio compare to Elanco Animal Health?

Which has more risk and volatility, ELAN or BLTE?

Does the media favor ELAN or BLTE?

Do analysts rate ELAN or BLTE?

Which has better valuation & earnings, ELAN or BLTE?

Is ELAN or BLTE more profitable?

Do insiders and institutionals hold more shares of ELAN or BLTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLTE vs. The Competition

Belite Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools